BOSTON SCIENTIFIC CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B |
| Cost of revenue | $6.2B | $5.3B | $4.3B | $4.0B | $3.7B |
| Gross profit | $13.9B | $11.5B | $9.9B | $8.7B | $8.2B |
| Selling, general & administrative | $6.9B | $6.0B | $5.2B | $4.5B | $4.4B |
| Research and development | $2.1B | $1.6B | $1.4B | $1.3B | $1.2B |
| Operating expenses | $10.2B | $8.9B | $7.6B | $7.1B | $7.0B |
| Operating income | $3.6B | $2.6B | $2.3B | $1.6B | $1.2B |
| Interest expense | $349.0M | $305.0M | $265.0M | $470.0M | $341.0M |
| Pretax income | $3.4B | $2.3B | $2.0B | $1.1B | $1.1B |
| Income tax expense | $493.0M | $436.0M | $393.0M | $443.0M | $36.0M |
| Net income | $2.9B | $1.8B | $1.6B | $698.0M | $1.0B |
| Balance Sheet | |||||
| Cash and equivalents | $2.0B | $414.0M | $865.0M | $928.0M | $1.9B |
| Current assets | $8.8B | $6.9B | $6.5B | $5.8B | $6.3B |
| Total assets | $43.7B | $39.4B | $35.1B | $32.5B | $32.2B |
| Current liabilities | $5.4B | $6.4B | $4.9B | $3.8B | $4.3B |
| Total debt | — | $10.7B | $9.1B | $8.9B | $9.1B |
| Stockholders' equity | $24.2B | $21.8B | $19.3B | $17.6B | $16.6B |
| Cash Flow Statement | |||||
| Cash from operations | $4.5B | $3.4B | $2.5B | $1.5B | $1.9B |
| Depreciation and amortization | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B |
| Stock-based compensation | $299.0M | $266.0M | $233.0M | $220.0M | $194.0M |
| Capital expenditure | $876.0M | $790.0M | $711.0M | $588.0M | $554.0M |
| Free cash flow | $3.7B | $2.6B | $1.8B | $938.0M | $1.3B |
| Dividends paid | — | $0 | $28.0M | $55.0M | $55.0M |
| Share repurchases | — | — | — | $0 | $0 |
| Impairments | $46.0M | $386.0M | $58.0M | $0 | $0 |
Shares outstanding 1.5B · Free float 99.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.